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Abstract 
Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, are amongst the 
most commonly used medications and produce their anti-inflammatory and analgesic 
benefits by blocking cyclooxygenase (COX)-2. These drugs also have the potential 
to prevent and treat cancer and some members of the class including ibuprofen can 
produce anti-platelet effects. Despite their utility, all NSAIDs are associated with 
increased risk of cardiovascular side effects which our recent work suggests could 
be mediated by increased levels of the endogenous NO synthase (NOS) inhibitor 
asymmetric dimethylarginine (ADMA) leading to reduced endothelial NOS activity 
and associated endothelial cell dysfunction. ADMA is a cardiotoxic hormone and 
biomarker of cardiovascular risk whose effects can be prevented by L-arginine. The 
ibuprofen salt, ibuprofen arginate (Spididol®) was created to increase drug solubility 
but we have previously established that it not only effectively blocks COX-2 but also 
provides an arginine source able to reverse the effects of ADMA in vitro and in vivo. 
Here we have gone on to explore whether the formulation of ibuprofen with arginine 
influences the potency and efficacy of the parent molecule using a range of simple in 
vitro assays designed to test the effects of NSAIDs on (i) platelet aggregation and 
(iii) colon cancer cell killing. Our findings demonstrate that ibuprofen arginate retains 
these key functional effects of NSAIDs with similar or increased potency compared 
to ibuprofen sodium, further illustrating the potential of ibuprofen arginate as an 
efficacious drug with the possibility of improved cardiovascular safety. 
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Introduction 
Ibuprofen is a relatively old member of the nonsteroidal anti-inflammatory drug 
(NSAID) class of medications that all work by blocking cyclooxygenase (COX) 
enzymes. COX has two isoforms; a house-keeping form, COX-1, which is 
constitutively expressed throughout the body and COX-2, which is an inducible 
isoform rapidly expressed at the site of inflammation[1] and in cancer[2, 3]. As such, 
COX-2 is the primary therapeutic target for NSAIDs in the treatment of pain, 
inflammation and cancer. However, COX-2 is also expressed constitutively in 
discreet regions of the body[4, 5] where its inhibition by NSAIDs causes the much-
reported cardiovascular side effects.  
 
Initially the cardiovascular side effects caused by NSAIDs were thought to be 
associated with COX-2 selective NSAIDs[6], such as Vioxx (rofecoxib), Bextra 
(valdecoxib) and Celebrex (celecoxib), introduced in the early 2000s to spare the 
gastrointestinal side effects caused by older style drugs. However, since all NSAIDs 
work by blocking COX-2 [7], we and others suggested that cardiovascular toxicity is 
a class effect [8], an idea that is now universally accepted [9] and most recently fully 
corroborated by the publication of two large clinical cardiovascular outcome studies, 
SCOT[10] (Europe) and PRECISION[11] (USA), showing that traditional NSAIDs 
including ibuprofen, particularly at higher daily doses, carry at least as great a 
cardiovascular risk as COX-2 selective drugs including celecoxib. Despite this 
ibuprofen remains the only conventional NSAIDs listed in WHO Model List of 
Essential Medicines 2015[12]. Clearly, then because ibuprofen usage is so firmly 
embedded within health care systems neither it’s over the counter status nor its 
global availability will likely be affected by the reporting of side effects it causes. This 
remains a curious situation within the COX-2 field since cardiovascular side effects 
caused by other members of the NSAID class, particularly the COX-2 selective 
drugs, have been the subject of intense media coverage including, in 2004, the 
events surrounding the dramatic withdrawal of rofecoxib.  
 
The mechanisms associated with the cardiovascular side effects caused by blocking 
COX-2 with NSAIDs are incompletely understood but are thought to involve the 
inhibition of cardio-protective prostanoids such as prostacyclin[7, 13]. It is now clear 
that COX-1 is the dominant driver of prostacyclin production in the systemic 
circulation[4, 14, 15] including under conditions of low-grade inflammation such as 
occurs in atherosclerosis[16]. With this in mind attention is increasingly turning to the 
kidney [5, 17], where COX-2 is constitutively expressed[5, 17, 18], to explain how 
NSAIDs cause cardiovascular side effects. This idea is supported by a new 
understanding of the origin of urinary metabolites of prostacyclin which are well 
established to be COX-2 driven and which our recent work shows can originate 
exclusively from the kidney [19]. Further to this our recent work shows that COX-2 in 
the kidney regulates plasma levels of asymmetric dimethylarginine (ADMA)[17]. 
ADMA is a well-recognised biomarker of cardiovascular risk that competes with L-
arginine to inhibit the cardioprotective production of vascular NO via endothelial nitric 
oxide synthase (eNOS). As such the cardiovascular compromise caused by ADMA 
can be prevented by arginine supplementation. 
 
Considering the popularity of ibuprofen and what we now know of its side effect 
profile, it is of particular importance to revisit what we understand of the mechanisms 
of action of this drug in all its formulations. Ibuprofen acid is relatively insoluble in 
aqueous solutions. To overcome this problem, by allowing for more rapid absorption 
from the stomach and hence faster pain relief, ibuprofen has been synthesised in a 
number of aqueous-soluble salt formulations. These include ibuprofen sodium and 
ibuprofen lysine, which are available worldwide, and ibuprofen arginate, which is 
available in South America, Italy, Spain and China but not in Northern Europe or 
North America. This latter formulation is particularly relevant as our recent work 
shows that following dissociation in aqueous solutions ibuprofen arginate effectively 
blocks COX-2 and, through the delivery of arginine, reverses eNOS compromise and 
endothelial dysfunction in vitro and in vivo[20]. At maximum recommended dosing 
ibuprofen arginate is predicted to deliver ≈2.g of arginine per day, which is sufficient 
according to one study, to cause beneficial cardiovascular effects in man [21]. Based 
on this study and on our preclinical observations we have suggested that ibuprofen 
arginate may have an improved cardiovascular profile compared to other 
preparations of the drug[20]. Whilst our bold claim needs to be tested in clinical 
studies the pharmacology of ibuprofen arginate compared to other formulations 
remains incompletely understood. Here in this study we have compared the potency 
and efficacy of ibuprofen sodium and ibuprofen arginate in two relevant in vitro 
pharmacological bioassays. Specifically we have investigated the effects of 
ibuprofen formulations on (i) inhibition of platelet aggregation and (ii) human colon 
cancer cell death. 
 
  
Materials and methods 
Materials 
Zambon (Italy) provided ibuprofen arginate. Unless stated otherwise all other drugs 
were obtained from Sigma Aldrich, UK. 
 
Solubility studies 
Ibuprofen formulations (0.01 -10 mM) were dissolved in 50 mM Tris buffer at pH 3 or 
pH 7 in 96-well plates. Solutions were incubated for 10 minutes at 37°C before 
absorbance was measured at 570 nm using a spectrophotometer (Infinite®F50; 
Tecan, Switzerland). 
 
Cell culture studies 
The human epithelial colorectal adenocarcinoma cell line, Caco-2 was purchased 
from American Type Culture Collection (Manassas, VA, USA) and cultured using 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% Foetal bovine serum 
(LabTech, UK), 2 mM L-glutamine, nonessential amino acids (Invitrogen, UK) and 
penicillin-streptomycin at 5% CO2 and 37°C. For drug treatments cells were plated in 
arginine free media at 1x103/well in 96 well plates and cultured for 96 hours before 
cell death was measured using Alamar Blue viability assays according to 
manufacturer’s instructions.  
 
Platelet aggregation studies 
This study was approved by the NHS St. Thomas’ Hospital Research Ethics 
Committee (reference 07/Q0702/24). All volunteers gave written informed consent 
before entering the study. Blood was collected by venepuncture into tri-sodium 
citrate (3.2% w/v final) from healthy volunteers who had abstained from NSAIDs for 
two weeks. Platelet aggregation in response to 1 mM arachidonic acid or 10 μM 
U46619 (Cayman Chemical Company) was measured in platelet rich plasma using a 
96-well plate platform as we have described previously[22, 23]. 
 
Statistical analysis 
Data is mean ± S.E.M for data from n= separate experiments/donors. For solubility 
experiments each n-value represents separate incubations. For cell based 
experiments drug treatment data was derived from separate individual wells and for 
control (vehicle) data derived from means of duplicate incubations on each 
experimental day. All statistical tests were performed using GraphPad Prism v5 
(GraphPad Inc., UK) and are defined in figure legends. Statistical significance (*) 
was assumed when p<0.05. 
  
Results 
Solubility of ibuprofen formulations 
As expected, ibuprofen acid was relatively insoluble in aqueous solutions at neutral 
(pH 7) or acidic (pH 3) pH, corresponding to blood and gastric fluid, respectively. 
However, ibuprofen sodium was relatively soluble at pH7 but not pH3 whilst 
ibuprofen arginate was readily soluble in aqueous solutions at either pH tested 
(Figure 1). 
 
Effects of ibuprofen salts on human colon cancer cell death 
It is now well accepted that COX-2 is an oncogene and that a broad range of 
NSAIDs kill cancer cells in vitro. The case for NSAIDs as chemotherapeutic agents is 
most established for celecoxib in colon cancer where in prospective clinical trials 
patients on the drug had around 50% less tumours than those on placebo[24]. 
Indeed celecoxib was licensed in Europe for the prevention of colon cancer until 
2011 when it was withdrawn due to safety concerns[3]. Here we have used the 
human colon cancer cell line, Caco-2, to assess the effects of ibuprofen salts on cell 
death. Celecoxib and the cancer killing drug doxorubicin were used as positive 
controls. Doxorubicin and celecoxib induced concentration dependent reductions in 
cell viability which reached a maximum of >90% cell death at 3 μM and 100 μM 
respectively (Figure 2). Ibuprofen arginate had relatively weak effects on cell viability 
with no response seen at concentrations up to 100 μM reflecting its lower potency as 
a COX-2 inhibitor compared to celecoxib[25]. However, at 1 mM, ibuprofen arginate 
but not ibuprofen sodium, caused a small but statistically significant reduction in 
Caco-2 cell viability (Figure 2). L-arginine at concentrations calculated to be 
equivalent to those delivered in fully dissociated ibuprofen arginate, arginine 
increased survival at 15-150 μM (p<0.001) with no effect seen at 0.5 mM (one-way 
ANOVA followed by Dunnett's test; p>0.05). 
 
Effects of ibuprofen salts on platelet aggregation 
Traditional NSAIDs such as ibuprofen can act as inhibitors of COX-1 and COX-2 
[26]. In the case of ibuprofen, which has higher affinity for COX-1 than COX-2, this 
means that at the therapeutic doses required to block COX-2 by ≈80%[25] COX-1 
will also be  strongly inhibited. COX-1 in platelets is responsible for thromboxane 
release, which activates platelets to aggregate. Consequently, blocking COX-1 in 
platelets inhibits aggregation induced by agents that work via the release of 
thromboxane such as arachidonic acid without affecting aggregation induced by 
exogenous thromboxane mimetics such as U46619. In man at therapeutic doses, the 
anti-platelet effects of NSAIDs are limited by their pharmacokinetics. Therefore the 
greatest anti-platelet effects are seen with irreversible (aspirin) and slowly 
metabolised (naproxen) NSAIDs with milder, but demonstrable effects of more 
rapidly metabolised drugs including ibuprofen[27, 28] and diclofenac. In this study we 
found that both ibuprofen sodium and ibuprofen arginate caused concentration 
dependent reductions in platelet aggregation induced by arachidonic acid but not by 
U46619 in vitro (Figure 3). Interestingly, whilst both salts of ibuprofen were effective, 
ibuprofen arginate was significantly more potent than ibuprofen sodium as an 
inhibitor of platelet aggregation (Figure 3). L-arginine at concentrations calculated to 
be equivalent to those delivered in fully dissociated ibuprofen arginate (up to 0.5 
mM) had no effect on platelet aggregation induced by either arachidonic acid or 
U46619 (one-way ANOVA followed by Dunnett's test; p>0.05). 
  
Discussion 
The cardiovascular side effects associated with NSAIDs are of major clinical 
concern. Whilst the specific mechanisms are unclear our previous work has 
identified ADMA as a potential biomarker and mediator of cardiovascular 
compromise associated with NSAID usage and consequent COX-2 blockade. ADMA 
competes with arginine in the vasculature leading to reduced eNOS activity which 
can be prevented by supplementation with the substrate L-arginine. Most recently we 
have shown that the arginine salt of ibuprofen, which is currently available as an 
over-the-counter drug, provides in one formulation an effective COX-2 inhibitor and 
substrate for eNOS.  
 
In addition to treating pain and inflammation, NSAIDs have other beneficial 
properties that for drugs like ibuprofen either (i) do not reach clinical significance or 
(ii) have not been tested in prospective clinical trials but remain important and 
relevant to assess. With this in mind, here we have extended the pharmacological 
assessment of ibuprofen arginate to include two relevant activities of NSAIDs (i) 
inhibition of platelet aggregation and (iii) cancer cell killing. Importantly, in addition to 
finding that ibuprofen arginate is effective at killing cancer cells, we found it to be 
more potent than the sodium salt as an inhibitor of platelet aggregation. Whilst these 
studies rely on in vitro assessments they provide promising preclinical evidence that 
ibuprofen arginate is not pharmacologically limited (compared to other salt 
formulations). This is crucial when considering the issue of cardiovascular side 
effects caused by NSAIDs because platelet activation and thrombosis are thought to 
be key underlying factors. Moreover, because it has recently been suggested that 
the anti-cancer effects of NSAIDs include two components, (i) inhibition of COX-2 in 
tumour cells and (ii) inhibition of platelet activation via blocking COX-1 in 
platelets[29, 30], ibuprofen arginate may not only represent a superior anti-
thrombotic to ibuprofen sodium but also in large populations may be better at 
preventing cancer. This work supports the idea that arginine formulations of NSAIDs 
should be further investigated for efficacy and for their potential to spare the 
cardiovascular system by supplying arginine.  
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Figure legends 
Figure 1: Solubility of ibuprofen formulations at pH3 (A) and pH7 (B). 
Data are mean ± SEM from n=3 separate experiments. Statistical significance was 
determined by two-way ANOVA with repeated measures and shown as *p<0.05 
when compared to ibuprofen acid. 
 
Figure 2: Cancer killing effects of doxorubicin (A), celecoxib (B) and ibuprofen 
salts (C).  
Data are mean ± SEM from n=6-8. Statistical significance was determined by either 
a one-way ANOVA with a Dunnets post-hoc test. 
 
Figure 3: Effect of Ibuprofen salts on platelet aggregation stimulated with 
arachidonic acid (A) or U46619 (B). 
Data are mean ± SEM from n=4. Statistical significance was determined by two-way 
ANOVA with repeated measures and shown as *p<0.05 when compared to ibuprofen 
sodium. 
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